210 related articles for article (PubMed ID: 32593915)
1. Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities.
de Vries G; Rosas-Plaza X; van Vugt MATM; Gietema JA; de Jong S
Cancer Treat Rev; 2020 Aug; 88():102054. PubMed ID: 32593915
[TBL] [Abstract][Full Text] [Related]
2. Targeted treatment approaches in refractory germ cell tumors.
Galvez-Carvajal L; Sanchez-Muñoz A; Ribelles N; Saez M; Baena J; Ruiz S; Ithurbisquy C; Alba E
Crit Rev Oncol Hematol; 2019 Nov; 143():130-138. PubMed ID: 31634730
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin resistance in germ cell tumours: models and mechanisms.
Jacobsen C; Honecker F
Andrology; 2015 Jan; 3(1):111-21. PubMed ID: 25546083
[TBL] [Abstract][Full Text] [Related]
4. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.
Koster R; van Vugt MA; Timmer-Bosscha H; Gietema JA; de Jong S
Expert Rev Mol Med; 2013 Sep; 15():e12. PubMed ID: 24074238
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations.
Oing C; Skowron MA; Bokemeyer C; Nettersheim D
Andrology; 2019 Jul; 7(4):487-497. PubMed ID: 30924611
[TBL] [Abstract][Full Text] [Related]
6. Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors.
Cavallo F; Feldman DR; Barchi M
Int J Dev Biol; 2013; 57(2-4):273-80. PubMed ID: 23784838
[TBL] [Abstract][Full Text] [Related]
7. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
Veenstra CM; Vaughn DJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.
Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C
Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452
[TBL] [Abstract][Full Text] [Related]
9. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
10. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
12. Intratesticular effects of cisplatin-based chemotherapy.
Dieckmann KP; Loy V
Eur Urol; 1995; 28(1):25-30. PubMed ID: 8521890
[TBL] [Abstract][Full Text] [Related]
13. Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent.
Piulats JM; Vidal A; García-Rodríguez FJ; Muñoz C; Nadal M; Moutinho C; Martínez-Iniesta M; Mora J; Figueras A; Guinó E; Padullés L; Aytés À; Molleví DG; Puertas S; Martínez-Fernández C; Castillo W; Juliachs M; Moreno V; Muñoz P; Stefanovic M; Pujana MA; Condom E; Esteller M; Germà JR; Capella G; Farré L; Morales A; Viñals F; García-Del-Muro X; Cerón J; Villanueva A
Clin Cancer Res; 2018 Aug; 24(15):3755-3766. PubMed ID: 29618620
[No Abstract] [Full Text] [Related]
14. Chemotherapy for good-risk germ cell tumors: current concepts and controversies.
Vaughn DJ
Urol Clin North Am; 2007 May; 34(2):171-7; abstract viii-ix. PubMed ID: 17484922
[TBL] [Abstract][Full Text] [Related]
15. [Testicular cancer - explanatory models for high cisplatin chemosensibility and new therapeutic options].
Ebbing J; Christoph F; Kempkensteffen C; Weikert S; Schostak M; Hinz S; Lein M; Miller K; Schrader M
Aktuelle Urol; 2008 Nov; 39(6):429-35. PubMed ID: 18979397
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in management of patients with platinum-refractory testicular germ cell tumors.
Kollmannsberger C; Nichols C; Bokemeyer C
Cancer; 2006 Mar; 106(6):1217-26. PubMed ID: 16463389
[TBL] [Abstract][Full Text] [Related]
17. Clonal analyses of refractory testicular germ cell tumors.
Barrett MT; Lenkiewicz E; Malasi S; Stanton M; Slack J; Andrews P; Pagliaro L; Bryce AH
PLoS One; 2019; 14(3):e0213815. PubMed ID: 30870501
[TBL] [Abstract][Full Text] [Related]
18. Re: First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG).
Richie JP
J Urol; 2015 Mar; 193(3):850. PubMed ID: 25765390
[No Abstract] [Full Text] [Related]
19. Disseminated testicular cancer: current chemotherapy strategies.
Williams SD; Loehrer PJ; Nichols CR; Roth BJ; Einhorn LH
Semin Oncol; 1989 Aug; 16(4 Suppl 6):105-9. PubMed ID: 2548281
[TBL] [Abstract][Full Text] [Related]
20. [The role of chemotherapy in the treatment of testicular cancer with the exception of seminomas].
Kenis Y; Piccart M; Beer M
Rev Med Brux; 1983 Apr; 4(4):219-23. PubMed ID: 6192477
[No Abstract] [Full Text] [Related]
[Next] [New Search]
